MRK - Merck & Co., Inc.

NYSE - NYSE Delayed Price. Currency in USD
74.50
+1.13 (+1.54%)
At close: 4:00PM EST
Stock chart is not supported by your current browser
Previous Close73.37
Open73.10
Bid0.00 x 1000
Ask0.00 x 800
Day's Range73.10 - 74.89
52 Week Range52.83 - 80.19
Volume12,460,467
Avg. Volume13,769,373
Market Cap193.728B
Beta (3Y Monthly)0.57
PE Ratio (TTM)60.32
EPS (TTM)1.24
Earnings DateFeb 1, 2019
Forward Dividend & Yield2.20 (2.95%)
Ex-Dividend Date2018-12-14
1y Target Est81.32
Trade prices are not sourced from all markets
  • 3 of the Top Big Pharma Stocks to Buy Now
    InvestorPlace12 hours ago

    3 of the Top Big Pharma Stocks to Buy Now

    The JPMorgan (NYSE:JPM) healthcare conference has brought greater awareness to the positive developments ahead for pharmaceutical stocks. Sure enough, the healthcare sector is up 1.3% Tuesday, with pharmaceutical stocks gaining a 1%. And although Big Pharma stocks are up because of the event, aided by a broad market rebound, there are still undervalued stocks in wider healthcare space. * 10 Growth Stocks With the Future Written All Over Them So what are the best stocks in Big Pharma that investors should pick up? The following pharmaceutical companies all have a track record of strong management, high-value product portfolios, and are on pace for continued growth in 2019. InvestorPlace - Stock Market News, Stock Advice & Trading Tips Source: Shutterstock ### AbbVie (ABBV) AbbVie Inc. (NYSE:ABBV) recapped its many achievements since becoming a public company in 2013. In that time, the company followed through on its mission to create an innovation-driven, patient-focused biotech company. Its revenue growth, which accelerated last year, is proof of its outstanding execution of delivering on new medicines. 2018 Achievements and Outlook: AbbVie expects to deliver on strong growth again this year. Even with biosimilars bringing more competition to its more than $6 billion HUMIRA business, it will ramp up its HCV business in 2018 and will make big investments this year to support new product launches. Imbruvica and Venclexta are two leading mechanisms in the biosimilars that will drive AbbVie's future growth. These investments, or operating costs as seen on the income statement, will pay off as it supports growth over the next decade. Growth Products: AbbVie's hematology and oncology franchise is already annualizing over $4 billion and is growing in the double-digit rates. Upadacitinib and risankizumab, if approved, will come to market later this year and add to revenue. Management affirmed its confidence in the business by authorizing a $5 billion share buyback. Investors interested in ABBV stock should note the upcoming $1.07 dividend. The stock trades ex-dividend on Jan. 14. Source: Shutterstock ### Regeneron Pharmaceuticals (REGN) Regeneron Pharmaceuticals (NASDAQ:REGN) is trending near 52-week highs for good reason. Its atopic dermatitis drug, Dupixent, has a strong prescription growth rate. Patients, despite the costs, are staying with the medication. Eyelea is another source of revenue. And Regeneron is now developing CAR-T therapies. CAR-T Science: Regeneron is effectively disconnecting the CAR-T cell from the CD28 system. In doing so, it will allow its scientists to mix and match them. By having combinatorial specificity, it is possible to get better targeting and higher efficacy for treatments. In the non-small cell lung cancer space, where Keytruda failed, Regeneron hopes its agent is at least as effective as Merck's (NYSE:MRK). * 10 A-Rated Stocks the Smart Money Is Piling Into Core Drivers: Regeneron's core revenue drivers continue to give investors confidence. As mentioned, Dupixent is working out very well for patients. In its last quarter, the drug's global sales were $260 million, or nearly $1 billion annualized. The drug will also treat asthma. Plus, the company has positive data in eosinophilic asthma for reductions in the exacerbations for pulmonary function tests. Given the market size for patients suffering from asthma, Regeneron's revenues are likely to grow at a faster pace than the market expects. Source: Shutterstock ### Amgen (AMGN) Amgen Inc. (NASDAQ:AMGN) highlighted its double-digit earnings per share growth targets at the JPMorgan conference. It will get there by improving its operating margin from 38% to 52%-54%. Saving $1.5 billion will give it the room it needs to raise its return on capital to its shareholders while continuing on its transformation. Growth Drivers: Amgen will launch nine new products in two therapeutic areas. It already increased its global presence from 50 countries (in 2011) to over 100 at the end of last year. Its high R&D investments include those in the genetics space. In particular, deCODE Genetics in Iceland is impressive because it has 1 million people outside of Iceland who are part of the effort. It also ended the year with 500,000 patients in the U.S. who are available to study genotypically and phenotypically. Products: Amgen has six cancer medicines that are in the early stages of product development. Drugs in this space make $4 billion in revenues for Amgen and grew in the double-digit rates in the last twelve months. Looking ahead, Amgen expects to have a strong portfolio of first-in-class molecules. With biospecifics, small molecules, large molecules, its BiTE platform and CAR-Ts, Amgen has the potential to exceed its own growth goals. As of this writing, Chris Lau did not hold a position in any of the aforementioned securities. ### More From InvestorPlace * 2 Toxic Pot Stocks You Should Avoid * 10 Companies That Could Post Decelerating Profits * 10 A-Rated Stocks the Smart Money Is Piling Into * Mizuho: 7 Long-Term Value Stocks to Buy Now Compare Brokers The post 3 of the Top Big Pharma Stocks to Buy Now appeared first on InvestorPlace.

  • Merck or AbbVie: Which Has the Better Cost Structure?
    Market Realist16 hours ago

    Merck or AbbVie: Which Has the Better Cost Structure?

    Merck & Co. or AbbVie: Which Is Performing Better This Month?(Continued from Prior Part)Expense guidanceIn its third-quarter earnings conference presentation, Merck & Co. (MRK) said that it expects its operating expenses to rise YoY

  • Stock Market News For Jan 15, 2019
    Zacks18 hours ago

    Stock Market News For Jan 15, 2019

    Benchmarks ended in the red on Monday as corporate earnings kicked off.

  • Merck or AbbVie: Which Has More Robust Margins?
    Market Realist18 hours ago

    Merck or AbbVie: Which Has More Robust Margins?

    Merck & Co. or AbbVie: Which Is Performing Better This Month?(Continued from Prior Part)Margin guidanceOn its third-quarter earnings conference call, Merck & Co. (MRK) forecast an expansion in its operating margin in the coming years, mainly

  • Markit19 hours ago

    See what the IHS Markit Score report has to say about Merck & Co Inc.

    # Merck & Co Inc ### NYSE:MRK View full report here! ## Summary * Perception of the company's creditworthiness is negative * Bearish sentiment is low ## Bearish sentiment Short interest | Positive Short interest is extremely low for MRK with fewer than 1% of shares on loan. This could indicate that investors who seek to profit from falling equity prices are not currently targeting MRK. ## Money flow ETF/Index ownership | Neutral ETF activity is neutral. The net inflows of $13.14 billion over the last one-month into ETFs that hold MRK are not among the highest of the last year and have been slowing. ## Economic sentiment PMI by IHS Markit | Neutral According to the latest IHS Markit Purchasing Managers' Index (PMI) data, output in the Healthcare sector is rising. The rate of growth is strong relative to the trend shown over the past year, but is easing. ## Credit worthiness Credit default swap | Negative The current level displays a negative indicator. MRK credit default swap spreads are near their highest levels for the past 1 year, which indicates the market's more negative perception of the company's credit worthiness. Please send all inquiries related to the report to score@ihsmarkit.com. Charts and report PDFs will only be available for 30 days after publishing. This document has been produced for information purposes only and is not to be relied upon or as construed as investment advice. To the fullest extent permitted by law, IHS Markit disclaims any responsibility or liability, whether in contract, tort (including, without limitation, negligence), equity or otherwise, for any loss or damage arising from any reliance on or the use of this material in any way. Please view the full legal disclaimer and methodology information on pages 2-3 of the full report.

  • Merck or AbbVie: Which Has a Stronger Earnings Trajectory?
    Market Realist19 hours ago

    Merck or AbbVie: Which Has a Stronger Earnings Trajectory?

    Merck & Co. or AbbVie: Which Is Performing Better This Month?(Continued from Prior Part)Earnings guidanceDuring its third-quarter earnings conference presentation, Merck & Co. (MRK) announced a change in its non-GAAP (generally accepted

  • 3 Big Stock Charts for Tuesday: Broadcom, Facebook and Merck
    InvestorPlace20 hours ago

    3 Big Stock Charts for Tuesday: Broadcom, Facebook and Merck

    Investors started the new trading week in the same lethargic mood they left the old one … not bearish so much as disinterested until they have more clarity. The S&P 500's close of 2,858.61 was 0.53% lower than Friday's close, leaving the market as much within reach of a renewed rally as it is on the verge of a correction. Total volume behind the pullback relatively light. Utility company PG&E (NYSE:PCG) led the way, losing a stunning 52% of its value after the organization announced it would be filing for chapter 11 bankruptcy. The company, which faces an enormous liability for its role in California's recent wildfires, recognizes it won't be able to handle that burden otherwise. Beyond that, however, the picture wasn't quite so grim. Citigroup (NYSE:C) jumped nearly 4% in response to a so-so fourth quarter report, while Goldcorp (NYSE:GG) gained more than 7% on Monday. The mega-bank anticipates impressive revenue growth this year, while the gold miner is to be bought by rival Newmont Mining (NYSE:NEM). Newmont shares subsequently fell nearly 9%, as the deal will be a dilutive all-stock deal that arguably overvalues Goldcorp at $10 billion. InvestorPlace - Stock Market News, Stock Advice & Trading Tips The best prospects for today's action, however, are names that are much less volatile. The stock charts of Facebook (NASDAQ:FB), Merck (NYSE:MRK) and Broadcom (NASDAQ:AVGO) have been quietly moving into grooves that have largely been overlooked, leaving each on the cusp of trade-worthy moves. ### Broadcom (AVGO) Back on Dec. 28, we pointed out Broadcom shares were in rally mode, and testing a key technical ceiling. That ceiling was closer to being tested the next two. That look is marked in the daily chart with a yellow arrow. Three days later, AVGO shares were in a freefall, calling the whole idea into question. * 10 A-Rated Stocks the Smart Money Is Piling Into The stock is back in rally mode though, and the next test of that very same technical ceiling is even better founded effort than the previous one was. The bulls are getting closer to that breakout move. Click to Enlarge • The technical ceiling in question is the upper boundary of a narrowing trading range, plotted with dashed lines on both stock charts. We've now logged weeks of higher lows. • Though shares of Broadcom were hammered on Jan. 3, all the key moving average lines have stepped up as support levels. Better yet, the purple 50-day moving average line just crossed above the white 200-day moving average line … a so-called "Golden Cross." • The upper boundary of the narrowing trading range is at $259. ### Facebook (FB) A little over a month ago, Facebook was in trouble. Between the threat of regulation and the reality of a customer revolt, the sellers inadvertently framed a falling trading ranges that chopped the value of the stock by more than a third. Shares broke out of that downtrend in December, though, and while it took an even lower low and then another bullish effort to finalize the bottom, that's happened too. Now there's just one more hurdle to clear if FB stock is going to start moving higher again. Click to Enlarge • The ceiling in question is around $146, where shares peaked in December, and so far have peaked this month. Monday's test of that ceiling was the strongest test yet. • In the meantime, the purple 50-day moving average line has been hurdled after it was a technical ceiling a month ago. • On the weekly chart of Facebook we're already in the shadow of a bullish MACD crossover … the first time it has been bullish since the middle of last year. ### Merck (MRK) Finally, had rival Pfizer (NYSE:PFE) and other pharma names not further defined similar moves, the pattern Merck has left behind of late wouldn't be remarkable. Given the clues at hand, however, investors can't afford to ignore the brewing risk. Merck and its peers have been unusually bullish since early last year, and that leaves them especially vulnerable right now. One more misstep could pull the rug out from underneath the group, and from MRK in particular. Click to Enlarge • When it was tested in October, the gray 100-day moving average line held up as a floor, sparking a move to higher highs. Ditto for the December test. Monday's test so far has been successful as well, but the repeated test of that floor can't be ignored. The bears continue to swing, and sooner than later will break that floor. • There is something different going on right now, however, that we've not seen in a while. That's strong selling volume. Two of the past three days have been high-volume selloffs, suggesting there are sellers waiting in the wings. • On the weekly chart, we've already logged a bearish MACD cross that technically killed last year's incredible uptrend. As of this writing, James Brumley did not hold a position in any of the aforementioned securities. You can follow him on Twitter, at @jbrumley. ### More From InvestorPlace * 2 Toxic Pot Stocks You Should Avoid * 10 Key Emerging-Market Stocks to Buy for Contrarian Investors * 7 Stocks at Risk of the Global Smartphone Slowdown * 7 Pharmaceutical Stocks That Just Raised Prices This Year Compare Brokers The post 3 Big Stock Charts for Tuesday: Broadcom, Facebook and Merck appeared first on InvestorPlace.

  • 5 Reasons Why Investors Should Buy Exelixis (EXEL) in 2019
    Zacksyesterday

    5 Reasons Why Investors Should Buy Exelixis (EXEL) in 2019

    Exelixis (EXEL) lead drug, Cabometyx continues to perform well.

  • Analysts’ Recommendations for AbbVie in January
    Market Realist2 days ago

    Analysts’ Recommendations for AbbVie in January

    Merck & Co. or AbbVie: Which Is Performing Better This Month? On January 10, AbbVie’s market cap was $132.91 billion. Based on its closing price on January 10, the company had reported returns of 2.21% in the last week, 0.67% in the last month, and -6.74% in the last quarter.

  • What's in Store for Merck in 2019 After a Solid Run in '18?
    Zacks2 days ago

    What's in Store for Merck in 2019 After a Solid Run in '18?

    Merck (MRK) looks well poised for 2019, carrying forward the momentum achieved last year.

  • Here's Why Merck & Co. Surged 35.8% in 2018
    Motley Fool2 days ago

    Here's Why Merck & Co. Surged 35.8% in 2018

    A big win for lung cancer patients could make Keytruda the world's top-selling cancer drug in a couple of years.

  • NASH Space in Focus in 2019 as Firms Look to Diversify
    Zacks4 days ago

    NASH Space in Focus in 2019 as Firms Look to Diversify

    NASH is a highly lucrative market with blockbuster potential. Hence, we take a look at some of the companies in this space.

  • 5 Reasons Why Investors Should Buy Novo Nordisk (NVO) in 2019
    Zacks4 days ago

    5 Reasons Why Investors Should Buy Novo Nordisk (NVO) in 2019

    Novo Nordisk (NVO) has a strong presence in the Diabetes care market and its top line is driven by strong performance of products like Victoza.

  • Pharma Stock Roundup: Lilly to Buy Loxo for $8B, M&A in Focus at JP Morgan Meet
    Zacks5 days ago

    Pharma Stock Roundup: Lilly to Buy Loxo for $8B, M&A in Focus at JP Morgan Meet

    Lilly (LLY) is spending $8 billion to buy small cancer biotech Loxo Oncology. Big Pharma CEOs hint at spur in M&A activity in 2019.

  • Dow 30 Stock Roundup: Boeing Q4 Commercial Deliveries Up Y/Y, Merck Buys NASH Candidate
    Zacks5 days ago

    Dow 30 Stock Roundup: Boeing Q4 Commercial Deliveries Up Y/Y, Merck Buys NASH Candidate

    The index enjoyed an excellent run this week and has now gained over five successive trading sessions.

  • 3 Biotech Stocks Bubbling Away
    Investopedia5 days ago

    3 Biotech Stocks Bubbling Away

    Merger and acquisition activity in the healthcare sector has biotech stocks soaring. Explore three stocks feeling the tailwind.

  • 4 Pharma & Biotech Pipeline Areas to Keep an Eye on in 2019
    Zacks5 days ago

    4 Pharma & Biotech Pipeline Areas to Keep an Eye on in 2019

    Here we present four therapeutic areas whose pipeline developments are expected to garner a lot of interest in 2019.

  • Big Pharma CEOs Indicate More M&A Deals at JP Morgan Meeting
    Zacks6 days ago

    Big Pharma CEOs Indicate More M&A Deals at JP Morgan Meeting

    Big pharma CEOs hint at spur in M&A activity in 2019 at the 37th J.P. Morgan Healthcare Conference.

  • Moderna Soars After Update of Its Pipeline Programs
    GuruFocus.com7 days ago

    Moderna Soars After Update of Its Pipeline Programs

    Moderna Inc. (MRNA) soared 4.2% to $16.95 per share on the New York Stock Exchange on Tuesday after the Cambridge, Massachusetts-headquartered biotechnology company had issued an update on several of its pipeline programs. Warning! GuruFocus has detected 1 Warning Sign with MRNA.

  • Moderna (MRNA) Announces Pipeline Progress, Shares Rise
    Zacks7 days ago

    Moderna (MRNA) Announces Pipeline Progress, Shares Rise

    Modern's pipeline of mRNA candidates, which are being developed for several cancer indications and rare diseases, is progressing well.

  • Novartis' Crizanlizumab Gets Breakthrough Therapy Status
    Zacks7 days ago

    Novartis' Crizanlizumab Gets Breakthrough Therapy Status

    Novartis's (NVS) crizanlizumab gets Breakthrough Therapy designation by the FDA for the prevention of VOCs in patients of all genotypes with SCD.

  • Dow Posts Longest Winning Run Since November: 5 Top Picks
    Zacks7 days ago

    Dow Posts Longest Winning Run Since November: 5 Top Picks

    The Dow - commenced 2019 on a brighter note. Positive developments on trade war front and Fed???s monetary stance are likely to boost investor sentiment in the near-term resulting in further consolidation of the index.

  • Markit7 days ago

    See what the IHS Markit Score report has to say about Merck & Co Inc.

    # Merck & Co Inc ### NYSE:MRK View full report here! ## Summary * Perception of the company's creditworthiness is negative * ETFs holding this stock are seeing positive inflows * Bearish sentiment is low ## Bearish sentiment Short interest | Positive Short interest is extremely low for MRK with fewer than 1% of shares on loan. This could indicate that investors who seek to profit from falling equity prices are not currently targeting MRK. ## Money flow ETF/Index ownership | Positive ETF activity is positive. Over the last month, growth of ETFs holding MRK is favorable, with net inflows of $24.85 billion. This is among the highest net inflows seen over the last one-year and the rate of additional inflows appears to be increasing. ## Economic sentiment PMI by IHS Markit | Neutral According to the latest IHS Markit Purchasing Managers' Index (PMI) data, output in the Healthcare sector is rising. The rate of growth is strong relative to the trend shown over the past year, but is easing. ## Credit worthiness Credit default swap | Negative The current level displays a negative indicator. MRK credit default swap spreads are at their highest levels for the past 3 years, which indicates the market's more negative perception of the company's credit worthiness. Please send all inquiries related to the report to score@ihsmarkit.com. Charts and report PDFs will only be available for 30 days after publishing. This document has been produced for information purposes only and is not to be relied upon or as construed as investment advice. To the fullest extent permitted by law, IHS Markit disclaims any responsibility or liability, whether in contract, tort (including, without limitation, negligence), equity or otherwise, for any loss or damage arising from any reliance on or the use of this material in any way. Please view the full legal disclaimer and methodology information on pages 2-3 of the full report.